FDA Approves METHYLPREDNISOLONE — Zydus Lifesciences Limited

# FDA Approves Generic Methylprednisolone Oral Formulation from Zydus Lifesciences Zydus Lifesciences Limited has received FDA approval for its generic methylprednisolone oral formulation (ANDA206751), expanding the competitive generic corticosteroid market and likely increasing price pressure on branded alternatives. The approval enables Zydus to capture additional market share in the widely-prescribed immunosuppressant segment, which could benefit healthcare payers and patients through lower medication costs.